Funded Biotechnology Startups in Palo Alto
Palo Alto's biotechnology sector has generated a wide range of funding events across the 26 companies shown here, with disclosed round sizes stretching fro…
Palo Alto's biotechnology sector has generated a wide range of funding events across the 26 companies shown here, with disclosed round sizes stretching from Epalex's $1M venture placement in November 2025 to a $500M raise by BridgeBio Pharma in February 2025 — the largest in the set alongside Ascendis Pharma's $500M post-IPO debt placement in March 2022. Six entries carry 2025 dates, led by BBOT's $261M round in August and Juvena Therapeutics' $31M close in July. A large share of rounds are labeled "Series Unknown," including several of the biggest.
Series A activity runs large in this cluster: Inceptive closed $100M at Series A in September 2023, and Pheast Therapeutics raised $76M at the same stage in April 2022. Four Series B deals appear in the dataset, ranging from Myome's $23M in June 2022 to Cognoa's $73M in November 2022. At the early end, Avenue Biosciences closed a $3M seed in October 2024 and Epalex recorded a $1M venture placement in November 2025.
Most recent rounds
26 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Palo Alto biotech companies in this dataset?
BridgeBio Pharma and Ascendis Pharma both raised $500M — BridgeBio via a Series Unknown round in February 2025 and Ascendis through post-IPO debt in March 2022. BBOT follows at $261M in August 2025, and Inceptive's $100M Series A from September 2023 is the largest labeled Series A in the set.
How much 2025 funding activity does this dataset capture for Palo Alto biotech?
Six of the 26 entries have 2025 round dates, spanning BridgeBio Pharma's $500M in February through Epalex's $1M venture placement in November. One of the six, HepaTx (May 2025), has an undisclosed amount, so the disclosed 2025 total understates actual capital raised.
Which round stages appear most frequently in this dataset?
"Series Unknown" is the most common classification, accounting for roughly 12 of the 26 entries (including one labeled "Venture - Series Unknown"). Series A appears six times and Series B four times. There is one Seed round (Avenue Biosciences, $3M, October 2024) and one Post-IPO Debt entry (Ascendis Pharma, $500M, March 2022).
How large do Series A rounds run among these companies?
The six labeled Series A rounds range from Leucine's $7M in October 2023 to Inceptive's $100M in September 2023. Three of the six exceed $20M: Inceptive ($100M), Pheast Therapeutics ($76M, April 2022), and ImpriMed ($23M, December 2023).
Which year in the dataset saw the most distinct funding events?
2023 accounts for eight of the 26 entries, the highest count for any single year in the set. That cohort includes Inceptive's $100M Series A, MapLight Therapeutics' $50M Series Unknown, Immune-Onc Therapeutics' $25M Series B, and five additional rounds across January through December.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.